Journal
EPILEPSY & BEHAVIOR CASE REPORTS
Volume 8, Issue -, Pages 44-46Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ebcr.2017.05.004
Keywords
Perampanel; Dentatombral-pallidoluysian atrophy; DRPLA; Progressive myoclonic epilepsy; Child
Categories
Funding
- Grants-in-Aid for Scientific Research [17K10072] Funding Source: KAKEN
Ask authors/readers for more resources
We administered perampanel (PER) to a bedridden 13-year-old male patient with dentatorubral-pallidoluysian atrophy (DRPLA). The DRPLA diagnosis was based on the presence of a CAG trinucleotide repeat in the ATN1 gene. The patient experienced continuous myoclonic seizures and weekly generalized tonic-clonic seizures (GTCs). PER stopped the patient's myoclonic seizures and reduced the GTCs to fragmented clonic seizures. The patient recovered his intellectual abilities and began to walk again with assistance. We suggest that PER be considered as one of the key drugs used to treat patients with DRPLA. (c) 2017 The Authors. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available